Table 2 Factors associated with 12-month mortality in univariate and multivariate analysis in patients admitted in the intensive care unit (ICU) within 60 days after last dose of immune checkpoint inhibitor (ICI)
OR for mortality (univariate logistic regression model) | OR for mortality (multivariate logistic regression model) | |
|---|---|---|
Reason for admission | ||
Immune-related adverse event | Ref | |
Intercurrent complication | 1.27 [0.98–1.65] | |
Complication of tumor progression | 1.59 [1.29–1.94] | 1.35 [1.14–1.59] |
Demographics and comorbidities | ||
Weight loss (> 5 kg in the 3 preceding months) | 1.24 [1.00–1.52] | |
Performance status > 2 | 1.27 [1.01–1.60] | 1.15 [0.94–1.40] |
Oncological characteristics | ||
Primary tumor site | ||
Non-small cell lung cancer | 1.24 [1.02–1.51] | 1.28 [1.07–1.52] |
Melanoma | 0.66 [0.54–0.78] | |
Metastatic disease at admission | 1.46 [1.10–1.93] | |
Length from ICI initiation (month) | 0.974 [0.951–0.997] | 0.973 [0.952–0.994] |
Clinical and biological characteristics at ICU admission | ||
SOFA Day 1 | 1.04 [1.01–1.07] | 1.05 [1.03–1.08] |
Neutrophil–lymphocyte ratio > 10 | 1.33 [1.09–1.62] | |
Treatments in ICU | ||
Mechanical ventilation | 1.19 [0.97–1.46] | |
Non-invasive ventilation | 1.25 [1.01–1.55] | |
Renal replacement therapy | 1.16 [0.79–1.71] | |
Steroids | 1.12 [0.92–1.36] | |